Jaguar Health Inc. [NASDAQ: JAGX] gained 2.20% on the last trading session, reaching $0.14 price per share at the time. The company report on October 26, 2022 that Jaguar Health Announces Publication in Breast Cancer Research and Treatment of Investigator-Initiated Phase 2 HALT-D Study of Crofelemer for Prevention of Chemotherapy-Induced Diarrhea (CID) in Breast Cancer Patients.
China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal
Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.
Simply click here and the name & trading symbol are yours.
Results of the study provide the first proof-of-concept data for potential use of crofelemer – a novel, oral, plant-based, non-opioid antidiarrheal prescription medication – in breast cancer patients.
Jaguar Health, Inc. (NASDAQ:JAGX) and its wholly owned subsidiary Napo Pharmaceuticals today announced the publication in the peer reviewed journal Breast Cancer Research and Treatment of the results of the investigator-initiated HALT-D trial evaluating crofelemer for preventing chemotherapy-induced diarrhea (CID) in HER2-positive breast cancer patients being treated with trastuzumab, pertuzumab and a taxane. These therapies cause CID in up to 80% of breast cancer patients, reaching grade 3, which often requires hospitalization, in 8-12% of patients. No antidiarrheal medications are currently approved that specifically target the underlying mechanism of CID.
Jaguar Health Inc. represents 119.86 million in outstanding shares, while the company has a total market value of $17.19 million with the latest information. JAGX stock price has been found in the range of $0.139 to $0.1445.
If compared to the average trading volume of 4.58M shares, JAGX reached a trading volume of 3233557 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Jaguar Health Inc. [JAGX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for JAGX shares is $4.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on JAGX stock is a recommendation set at 1.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Cantor Fitzgerald have made an estimate for Jaguar Health Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on July 07, 2021. While these analysts kept the previous recommendation, Rodman & Renshaw raised their target price to Buy. The new note on the price target was released on July 11, 2017, representing the official price target for Jaguar Health Inc. stock.
The Average True Range (ATR) for Jaguar Health Inc. is set at 0.01, with the Price to Sales ratio for JAGX stock in the period of the last 12 months amounting to 2.07. The Price to Book ratio for the last quarter was 4.80, with the Price to Cash per share for the same quarter was set at 0.08.
Trading performance analysis for JAGX stock
Jaguar Health Inc. [JAGX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -2.24. With this latest performance, JAGX shares dropped by -11.92% in over the last four-week period, additionally sinking by -69.73% over the last 6 months – not to mention a drop of -94.19% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for JAGX stock in for the last two-week period is set at 37.46, with the RSI for the last a single of trading hit 39.56, and the three-weeks RSI is set at 36.53 for Jaguar Health Inc. [JAGX]. The present Moving Average for the last 50 days of trading for this stock 0.1923, while it was recorded at 0.1432 for the last single week of trading, and 0.4040 for the last 200 days.
Jaguar Health Inc. [JAGX]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Jaguar Health Inc. [JAGX] shares currently have an operating margin of -939.05 and a Gross Margin at +46.18. Jaguar Health Inc.’s Net Margin is presently recorded at -1213.26.
Return on Equity for this stock declined to -365.08, with Return on Assets sitting at -109.45.
Jaguar Health Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.70 and a Current Ratio set at 1.00.
Jaguar Health Inc. [JAGX]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for JAGX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Jaguar Health Inc. go to 40.00%.
An analysis of insider ownership at Jaguar Health Inc. [JAGX]
There are presently around $1 million, or 4.90% of JAGX stock, in the hands of institutional investors. The top three institutional holders of JAGX stocks are: VANGUARD GROUP INC with ownership of 2,212,248, which is approximately 105.687% of the company’s market cap and around 0.10% of the total institutional ownership; RENAISSANCE TECHNOLOGIES LLC, holding 1,186,744 shares of the stock with an approximate value of $0.17 million in JAGX stocks shares; and BLACKROCK INC., currently with $94000.0 in JAGX stock with ownership of nearly -14.733% of the company’s market capitalization.
Positions in Jaguar Health Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 15 institutional holders increased their position in Jaguar Health Inc. [NASDAQ:JAGX] by around 1,634,459 shares. Additionally, 19 investors decreased positions by around 1,292,657 shares, while 5 investors held positions by with 2,985,645 shares. The mentioned changes placed institutional holdings at 5,912,761 shares, according to the latest SEC report filing. JAGX stock had 7 new institutional investments in for a total of 88,173 shares, while 13 institutional investors sold positions of 624,061 shares during the same period.